Drug
PF 04958242
PF 04958242: highest development phase Phase 2, developed by Biogen. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| PF-04958242 NCT02855411 | Phase 2 | Cognitive Impairment Associated With Schizophrenia (CIAS) |
| PF-04958242 NCT01365338 | Phase 1 | Healthy Volunteer |
| PF-04958242 NCT01518920 | Phase 1 | Hearing Loss, Sensorineural |
Latest
No recent events.
Follow PF 04958242 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.